Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study
Abstract Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a new cancer drug to market. However, many development efforts are aimed at extending the label of already approved drugs. Herein, we...
Main Authors: | Charlotte Ouimet, Nora Hutchinson, Catherine Wang, Carol Matyka, Joseph C. Del Paggio, Jonathan Kimmelman |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-42213-y |
Similar Items
-
Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study.
by: Charlotte Ouimet, et al.
Published: (2022-01-01) -
The proportion of randomized controlled trials that inform clinical practice
by: Nora Hutchinson, et al.
Published: (2022-08-01) -
The SquAd derivation: A Square Additive approach to the turbulent Prandtl number [version 3; peer review: 1 approved, 3 approved with reservations, 1 not approved]
by: Vincent Moreau
Published: (2023-09-01) -
An Efficient Approach to Obtaining Large Numbers of Distant Supernova Host Galaxy Redshifts
by: Lidman, C, et al.
Published: (2013) -
Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis
by: Nora Hutchinson, et al.
Published: (2022-12-01)